FIELD: biotechnology, experimental oncology.
SUBSTANCE: genetically and phenotypically stable cell line is obtained using artificial stimulation of CD95-positive cell apoptosis by action of effector anti-CD95 monoclonal antibodies. Said cell line fully retains hystogenetic phenotype of T-lymphoblastic leukemia without expression of CD95(Fas/APO-1) receptor. Method of present invention is useful in screening of antitumor agents, in particular synthetic and natural substances having antitumor activity, as well as in screening of preparations having antitumor action without induction of tumor cell apoptosis.
EFFECT: new method for screening of antitumor agents.
6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF TRIINDOLYL METHANE DERIVATIVES AS ANTICANCER DRUGS | 2010 |
|
RU2454232C2 |
| PHARMACEUTICAL COMPOSITION BASED ON TRIINDOLYLMETHANE DERIVATIVE AS ANTI-TUMOUR MEDICATION | 2012 |
|
RU2549430C2 |
| METHOD FOR TUMOUR CELL DEATH INDUCTION | 2015 |
|
RU2620165C2 |
| INHIBITORS OF CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS | 2013 |
|
RU2652348C2 |
| AGENT STIMULATING APOPTOSIS OF HUMAN LEUKAEMIA CELLS | 2007 |
|
RU2360692C1 |
| METHOD FOR LIABILITY TO DEVELOPMENT OF ATHEROSCLEROSIS IN MIDDLE-AGED MEN | 2020 |
|
RU2738975C1 |
| USING OPIOIDS OR OPIOID MIMETICS FOR TREATING PATIENTS WITH PERSISTENT MALIGNANT TUMOUR | 2009 |
|
RU2520636C2 |
| APOPTOSIS DETECTION TECHNIQUES AND REAGENTS | 2007 |
|
RU2450273C2 |
| PHARAMCEUTICAL COMPOSITION FOR TREATMENT OF ONCOLOGICAL DISEASES | 2012 |
|
RU2484814C1 |
| METHOD OF PRODUCING HUMAN RECOMBINANT ANTI-TUMOUR PROTEIN DR5-B | 2018 |
|
RU2687435C1 |
